Skip to content

Trial Summary

A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas



ACTRN/NCT /ethics:


Scientific title:

A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS5001, an Anti-ROR1 Antibody Drug Conjugate, in Patients with Advanced Solid Tumors and Lymphomas

Sponsor / Cooperative group:


Trial & Patient Characteristics

Cancer TypeAll cancers; Lymphoma
Trial TypeTreatment
PhasePhase I
Age Range18 years and older
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced
Anticipated Start Date2022-03-28
Anticipated End Date2024-03-31

Participating Hospitals

HospitalIcon Cancer Centre - Tennyson and Windsor Garden
Clinical Trial CoordinatorSue Yeend
Phone08 8292 2204
Principal InvestigatorSarwan Bishnoi
Recruitment StatusRecruiting